Singapore markets closed
Straits Times Index
3,343.35 +11.65 (+0.35%) S&P 500
5,486.40 +8.50 (+0.16%) Dow
39,235.03 +107.23 (+0.27%) Nasdaq
17,851.65 +46.50 (+0.26%) Bitcoin USD
61,960.74 +346.20 (+0.56%) CMC Crypto 200
1,294.91 +28.77 (+2.27%)
PCVX Oct 2024 90.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:15PM EDT. Market open.
| Previous close | 24.10 |
| Open | 24.10 |
| Bid | 22.10 |
| Ask | 26.80 |
| Strike | 90.00 |
| Expiry date | 2024-10-18 |
| Day's range | 24.10 - 24.11 |
| Contract range | N/A |
| Volume | |
| Open interest | 33 |
Simply Wall St.We're Hopeful That Vaxcyte (NASDAQ:PCVX) Will Use Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although...
- GuruFocus.com
Vaxcyte Inc (PCVX) Reports Q1 2024 Earnings: A Detailed Financial and Operational Overview
Consistent with Analyst Projections Amidst Strategic Advancements
GlobeNewswireVaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
© 2024 Yahoo. All rights reserved.